

Rewiring Recovery: Psychedelic-Assisted Therapy for Addiction

Audrey Tharp, M.Sc.

References

1. Substance Abuse and Mental Health Services Administration (SAMHSA). Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health. Rockville, MD: SAMHSA; 2023.
2. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2023. Vienna: United Nations; 2023.
3. National Institute on Drug Abuse (NIDA). 2020.
4. Hasin DS, O'Brien CP, Auriacombe M, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. *Am J Psychiatry*. 2013;170(8):834–851.
5. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. *Lancet Psychiatry*. 2016;3(8):760–773.
6. Everitt BJ, Robbins TW. Drug addiction: updating actions to habits to compulsions ten years on. *Annu Rev Psychol*. 2016;67:23–50.
7. Volkow ND, Michaelides M, Baler R. The neuroscience of drug reward and addiction. *Physiol Rev*. 2019;99(4):2115–2140.
8. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. *Science*. 1997;275(5306):1593–1599.
9. Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. *Nat Rev Neurosci*. 2011;12(11):652–669.
10. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. *Brain Res Rev*. 1993;18(3):247–291.
11. National Institute on Drug Abuse (NIDA). Principles of Drug Addiction Treatment: A Research-Based Guide. 3rd ed. Bethesda, MD: National Institute on Drug Abuse; 2018.
12. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? *Addiction*. 2013;108(2):275–293. doi:10.1111/j.1360-0443.2012.04054.x.
13. Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. *Nat Rev Neurosci*. 2020;21(11):611–624. doi:10.1038/s41583-020-0367-2.
14. Alcohol and Drug Foundation. The Drug Wheel. Alcohol and Drug Foundation.
15. The Drugs Wheel. The Drugs Wheel: An Educational Harm Reduction Tool.
16. de Vos CMH, Mason NL, Kuypers KPC. Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics. *Front Psychiatry*. 2021;12:724606. doi:10.3389/fpsyt.2021.724606.
17. Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. *J Psychopharmacol*. 2008;22(6):603–620. doi:10.1177/0269881108093587.
18. Hartogsohn I. Constructing drug effects: a history of set and setting. *Drug Sci Policy Law*. 2017;3:2050324516683325. doi:10.1177/2050324516683325.
19. Kelly JR, Gillan CM, Prenderville J, et al. Psychedelic therapy in the treatment of addiction: the past, present and future. *Front Psychiatry*. 2023;14:1183740.
20. Piper T, Small F, Brown S, Kelleher M, Mitcheson L, Rucker J, et al. Psychedelic-assisted treatment for substance use disorder: a narrative systematic review. *Addiction*. 2025. doi:10.1111/add.16762.

21. Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. *JAMA Psychiatry*. 2022;79(10):953–962. doi:10.1001/jamapsychiatry.2022.2096.
22. Rieser NM, Bitar R, Halm S, et al. Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial. *eClinicalMedicine*. 2025;82:103149. doi:10.1016/j.eclinm.2025.103149.
23. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT_{2A} receptor agonist psilocybin in the treatment of tobacco addiction. *J Psychopharmacol*. 2014;28(11):983–992.
24. Domingues CC, et al. Ayahuasca for the treatment of alcohol use disorder. In: *Neurobiology and Physiology of Substance Use Disorders*. Elsevier; 2024.
25. Barbosa PCR, et al. Assessment of alcohol and tobacco use disorders among religious users of ayahuasca. *Front Psychol*. 2018.
26. Malcolm BJ, et al. A systematic literature review of clinical trials and therapeutic applications of ibogaine. *J Subst Abuse Treat*. 2021.
27. Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Treatment of Substance Use Disorders — A Scoping Review. Pharmaceuticals. 2026.
28. Sarparast A, et al. MDMA-assisted psychotherapy for alcohol use disorder: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3-month follow-up. *Alcohol Alcohol*. 2025.
29. Grabski M, McAndrew A, Lawn W, et al. Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder: a randomised controlled trial. *Am J Psychiatry*. 2022;179(2):152–162.
30. Krebs TS, Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. *J Psychopharmacol*. 2012;26(7):994–1002.
31. ClinicalTrials.gov. DMT-assisted psychotherapy for moderate-to-severe alcohol use disorder. ClinicalTrials.gov Identifier: NCT06070649.
32. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. *J Psychopharmacol*. 2015;29(3):289–299. doi:10.1177/0269881114565144.
33. Jensen ME, Stenbæk DS, Messell CD, et al. Single-dose psilocybin therapy for alcohol use disorder: pharmacokinetics, feasibility, safety and efficacy in an open-label study. *J Psychopharmacol*. 2025. doi:10.1177/02698811251319457.
34. Pagni BA, Zeifman RJ, Mennenga SE, et al. Multidimensional personality changes following psilocybin-assisted therapy in patients with alcohol use disorder. *Am J Psychiatry*. 2025;182(1):114–125. doi:10.1176/appi.ajp.20230887.
35. Carhart-Harris RL, Friston KJ. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. *Pharmacol Rev*. 2019;71(3):316–344. doi:10.1124/pr.118.017160.